title: SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer.
abstract: Practical experience with cancer vaccines combined with accumulated knowledge of the complex interactions between cancer and immune system rationalize the combinatorial use of immune adjuvants for better efficacy. We recently described a novel adjuvant system based on the costimulatory SA-4-1BBL and TLR4 agonist MPL that has desired therapeutic and safety profiles.
authors.affiliation: Institute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; Present affiliation: Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD USA.
authors.forename: Abhishek K
authors.initials: AK
authors.lastname: Srivastava
authors.affiliation: Institute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville , Louisville, KY, USA.
authors.forename: Esma S
authors.initials: ES
authors.lastname: Yolcu
authors.affiliation: Institute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; Present affiliation: Ahi Evran University, School of Medicine, Department of Medical Biyology, Kirsehir, Turkey.
authors.forename: Gunes
authors.initials: G
authors.lastname: Dinc
authors.affiliation: Institute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville , Louisville, KY, USA.
authors.forename: Rajesh K
authors.initials: RK
authors.lastname: Sharma
authors.affiliation: Institute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
authors.forename: Haval
authors.initials: H
authors.lastname: Shirwan
keywords: Adjuvant systems; CD137; MPL; SA-4-1BBL; TLR; cancer vaccines; lung cancer